Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients

Clinical Infectious Diseases

Volumn 38, Issue SUPPL. 4, 2004, Pages

  Martinez, Fernando J ^a,b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN DERIVATIVE; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTRIAXONE; CEFUROXIME; CEPHALOSPORIN; CIPROFLOXACIN; CLARITHROMYCIN DERIVATIVE; CLAVULANIC ACID; COTRIMOXAZOLE; DOXYCYCLINE; ERYTHROMYCIN; GATIFLOXACIN; GEMIFLOXACIN; LEVOFLOXACIN; MACROLIDE; MOXIFLOXACIN; OFLOXACIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; QUINOLONE DERIVATIVE; TICARCILLIN; VANCOMYCIN;

CLINICAL TRIAL; COHORT ANALYSIS; COMMUNITY ACQUIRED PNEUMONIA; DISEASE SEVERITY; DRUG CHOICE; DRUG COST; DRUG EFFICACY; ECONOMIC ASPECT; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; IMMUNOMODULATION; LENGTH OF STAY; MEDICAL SPECIALIST; MONOTHERAPY; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIMARY HEALTH CARE; PRIORITY JOURNAL; REVIEW; STATISTICAL ANALYSIS; STREPTOCOCCUS PNEUMONIA;

ANTI-INFECTIVE AGENTS; AZA COMPOUNDS; COMMUNITY-ACQUIRED INFECTIONS; DOXYCYCLINE; DRUG THERAPY, COMBINATION; FLUOROQUINOLONES; HOSPITALIZATION; HUMANS; MACROLIDES; NAPHTHYRIDINES; OFLOXACIN; OUTCOME ASSESSMENT (HEALTH CARE); PNEUMONIA, BACTERIAL; QUINOLINES; RETROSPECTIVE STUDIES;

EID: 2442705225     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/382689     Document Type: Review

References (77)

1. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of community-acquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000; 31:347-82.
2. Niederman MS, Mandell LA, Anzueto A, et al. Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am J Respir Crit Care Med 2001; 163:1730-54.
3. Mandell LA, Marrie TJ, Grossman RF, Chow AW, Hyland RH. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. The Canadian Community-Acquired Pneumonia Working Group. Clin Infect Dis 2000; 31:383-421.
4. Heffelfinger JD, Dowell SF, Jorgensen JH, et al. Management of community-acquired pneumonia in the era of pneumococcal resistance. A report from the drug-resistant Streptococcus pneumoniae therapeutic working group. Arch Intern Med 2000; 160:1399-408.
5. British Thoracic Society (BTS) Standards of Care Committee. BTS guidelines for the management of community acquired pneumonia in adults. Thorax 2001; 56(Suppl 4):IV1-64.
6. Gilbert K, Gleason PP, Singer DE, et al. Variations in antimicrobial use and cost in more than 2000 patients with community-acquired pneumonia. Am J Med 1998; 104:17-27.
7. Gleason PP, Meehan TP, Fine JM, Galusha DH, Fine MJ. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia. Arch Intern Med 1999; 159:2562-72.
8. Dudas V, Hopefl A, Jacobs R, Guglielmo BJ. Antimicrobial selection for hospitalized patients with presumed community-acquired pneumonia: a survey of nonteaching US community hospitals. Ann Pharmacother 2000; 34:446-52.
9. Houck PM, MacLehose RF, Niederman MS, Lowery JK. Empiric antibiotic therapy and mortality among Medicare pneumonia inpatients in 10 Western states - 1993, 1995, and 1997. Chest 2001; 119:1420-6.
10. Malone DC, Shaban HM. Adherence to ATS guidelines for hospitalized patients with community-acquired pneumonia. Ann Pharmacother 2001; 35:1180-5.
11. Niederman MS, Bass JB, Campbell GD, et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity, and initial antimicrobial therapy. American Thoracic Society, Medical Section of the American Lung Association. Am Rev Respir Dis 1993; 148:1418-26.
12. Menendez R, Ferrando D, Valles JM, Vallterra J. Influence of deviation from guidelines on the outcome of community-acquired pneumonia. Chest 2002; 122:612-7.
13. Rello J, Catalan M, Diaz E, Bodi M, Alvarez B. Association between empirical antimicrobial therapy at the hospital and mortality in patients with severe community-acquired pneumonia. Intensive Care Med 2002; 28:1030-5.
14. Rello J, Rodriguez R, Jubert P, Alvarez B, Study Group for Severe Community-Acquired Pneumonia. Severe community-acquired pneumonia in the elderly. Clin Infect Dis 1996; 23:723-8.
15. Stahl JE, Barza M, DesJardin J, Martin R, Eckman MH. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia. Arch Intern Med 1999; 159:2576-80.
16. Laing RBS, Mackenzie AR, Shaw H, Gould IM, Douglas JM. Duration of intravenous therapy and hospital stay according to choice of empirical antimicrobial treatment for community-acquired respiratory infection. Int J Antimicrob Agents 1999; 13:53-6.
17. Burgess DS, Lewis JS II. Effect of macrolides as part of initial empiric therapy on medical outcomes for hospitalized patients with community-acquired pneumonia. Clin Ther 2000; 22:872-8.
18. Lentino JR, Krasnicka B. Association between initial empirical therapy and decreased length of stay among veteran patients hospitalized with community acquired pneumonia. Int J Antimicrob Agents 2002; 19:61-6.
19. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997; 336:243-50.
20. Dowell SF. The best treatment for pneumonia. New clues, but no definite answers. Arch Intern Med 1999; 159:2511-2.
21. Niederman MS. How do we optimize outcomes for patients with severe community-acquired pneumonia? Intensive Care Med 2002; 28:1003-5.
22. Mufson MA, Stanek RJ. Bacteremic pneumococcal pneumonia in one American city: a 20-year longitudinal study, 1978-1997. Am J Med 1999; 107(1A):34S-43S.
23. Waterer GW, Somes GW, Wunderink RG. Monotherapy may be suboptimal for severe bacteremic pneumococcal pneumonia. Arch Intern Med 2001; 161:1837-42.
24. Martinez JA, Horcajada JP, Almela M, et al. Addition of a macrolide to a β-lactam-based empirical antibiotic regimen is associated with lower in-hospital mortality for patients with bacteremic pneumococcal pneumonia. Clin Infect Dis 2003; 36:389-95.
25. File TM Jr, Mandell LA. What is optimal antimicrobial therapy for bacteremic pneumococcal pneumonia? Clin Infect Dis 2003; 36:396-8.
26. Vergis EN, Inforf A, File TM Jr, et al. Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients. Arch Intern Med 2000; 160:1294-300.
27. Paladino JA, Gudgel LD, Forrest A, Niederman MS. Cost-effectiveness of IV-to-oral switch therapy. Azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122:1271-9.
28. Plouffe J, Schwartz DB, Kolokathis A, et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob Agents Chemother 2000; 44:1796-802.
29. Dresser LD, Niederman MS, Paladino JA. Cost-effectiveness of gatifloxacin vs ceftriaxone with a macrolide for the treatment of community-acquired pneumonia. Chest 2001; 119:1439-48.
30. Fogarty C, Dowell ME, Ellison WT. Treating community-acquired pneumonia in hospitalized patients: gatifloxacin vs ceftriaxone/clarithromycin. J Respir Dis 1999; 20(Suppl A):S60-9.
31. File TM Jr, Segreti J, Dunbar L, et al. A multicenter, randomized study comparing the efficacy and safety of intravenous and/or oral levofloxacin versus ceftriaxone and/or cefuroxime axetil in treatment of adults with community-acquired pneumonia. Antimicrob Agents Chemother 1997; 41:1965-72.
32. Frank E, Liu J, Kinasewitz G, et al. A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin Ther 2002; 24:1292-308.
33. Finch R, Schurmann D, Colllins O, et al. Randomized controlled trial of sequential intravenous (i.v.) and oral moxifloxacin compared with sequential i.v. and oral co-amoxiclav with or without clarithromycin in patients with community-acquired pneumonia requiring initial parenteral treatment. Antimicrob Agents Chemother 2002; 46:1746-54.
34. Lode H, File TM Jr, Mandell LA, et al. Oral gemifloxacin versus sequential therapy with intravenous ceftriaxone/oral cefuroxime with or without a macrolide in the treatment of patients hospitalized with community-acquired pneumonia: a randomized, open-label, multicenter study of clinical efficacy and tolerability. Clin Ther 2002; 24:1915-36.
35. Lynch JP III, Martinez FJ. Clinical relevance of macrolide-resistant Streptococcus pneumoniae for community-acquired pneumonia. Clin Infect Dis 2002; 34(Suppl 1):S27-46.
36. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Vandervoort MK, Feagan BG. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. CAPITAL Study Investigators. Community-acquired pneumonia intervention trial assessing levofloxacin. JAMA 2000; 283:749-55.
37. Marrie TJ, Lau CY, Wheeler SL, Wong CJ, Feagan BG. Predictors of symptom resolution in patients with community-acquired pneumonia. Clin Infect Dis 2000; 31:1362-7.
38. Zhanel GG, Ennis K, Vercaigne L, et al. A critical review of the fluoroquinolones. Focus on respiratory tract infections. Drugs 2002; 62:13-59.
39. File TM Jr. Appropriate use of antimicrobials for drug-resistant pneumonia: focus on the significance of β-lactam-resistant Streptococcus pneumoniae. Clin Infect Dis 2002; 34(Suppl 1):S17-26.
40. Daily P, Gelling L, Rothrock G, et al. Resistance of Streptococcus pneumoniae to fluoroquinolones - United States, 1995-1999. MMWR Morb Mortal Wkly Rep 2001; 50:800-4.
41. Brueggeman AB, Coffman SL, Rhomberg P, et al. Fluoroquinolone resistance in Streptococcus pneumoniae in United States since 1994-1995. Antimicrob Agents Chemother 2002; 46:680-8.
42. Klugman KP. Bacteriological evidence of antibiotic failure in pneumococcal lower respiratory tract infections. Eur Respir J Suppl 2002; 36:3s-8s.
43. Jacobs MR. In vivo veritas: in vitro macrolide resistance in systemic Streptococcus pneumoniae infections does result in clinical failure. Clin Infect Dis 2002; 35:565-9.
44. Khair OA, Devalia JL, Abdelaziz MM, Sapsford RJ, Davies RJ. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8, and sICAM-1 by cultured human bronchial epithelial cells. Eur Respir J 1995; 8:1451-7.
45. Sugiyama Y, Yanagisawa K, Tominaga SI, Kitamura S. Effects of long-term administration of erythromycin on cytokine production in rat alveolar macrophages. Eur Respir J 1999; 14:1113-6.
46. Khan AA, Slifer TR, Araujo FG, Remington JS. Effect of clarithromycin and azithromycin on production of cytokines by human monocytes. Int J Antimicrob Agents 1999; 11:121-32.
47. Morikawa K, Watabe H, Araake M, Morikawa S. Modulatory effect of antibiotics on cytokine production by human monocytes in vitro. Antimicrob Agents Chemother 1996; 40:1366-70.
48. Kohyama T, Takizawa H, Kawasaki S, Akiyama N, Sato M, Ito K. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors. Antimicrob Agents Chemother 1999; 43:907-11.
49. Fujita K, Shimizu T, Majima Y, Sakakura Y. Effects of macrolides on interleukin-8 secretion from human nasal epithelial cells. Eur Arch Otorhinolaryngol 2000; 257:199-204.
50. Anderson R. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation. J Infect Dis 1989; 159:966-73.
51. Labro MT, el Benna J, Babin-Chevaye C. Comparison of the in-vitro effect of several macrolides on the oxidative burst of human neutrophils. J Antimicrob Chemother 1989; 24:561-72.
52. Aoshiba K, Nagai A, Konno K. Erythromycin shortens neutrophil survival by accelerating apoptosis. Antimicrob Agents Chemother 1995; 39:872-7.
53. Nagai H, Shishido H, Yoneda R, Yamaguchi E, Tamura A, Kurashima A. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis. Respiration 1991; 58:145-9.
54. Sakito O, Kadota J, Kohno S, Abe K, Shirai R, Hara K. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: a potential mechanism of macrolide therapy. Respiration 1996; 63:42-8.
55. Tredaniel J, Zalcman G, Gerber F, et al. Diffuse panbronchiolitis: efficacy of low-dose erythromycin. Respir Med 1993; 87:229-30.
56. Jaffe A, Francis J, Rosenthal M, Bush A. Long-term azithromycin may improve lung function in children with cystic fibrosis. Lancet 1998; 351:420.
57. Equi A, Balfour-Lynn IM, Bush A, Rosenthal M. Long term azithromycin in children with cystic fibrosis: a randomised, placebo-controlled crossover trial. Lancet 2002; 360:978-84.
58. Wolter J, Seeney S, Bell S, Bowler S, Masel P, McCormack J. Effect of long term treatment with azithromycin on disease parameters in cystic fibrosis: a randomised trial. Thorax 2002; 57:212-6.
59. Tsang KWT, Ho PI, Chan KN, et al. A pilot study of low-dose erythromycin in bronchiectasis. Eur Respir J 1999; 13:361-4.
60. Suzuki T, Yanai M, Yamaya M, et al. Erythromycin and common cold in COPD. Chest 2001; 120:730-3.
61. Puren AJ, Feldman C, Savage N, Becker PJ, Smith C. Patterns of cytokine expression in community-acquired pneumonia. Chest 1995; 107:1342-9.
62. Glynn P, Coakely R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999; 54:51-5.
63. Antunes G, Evans SA, Lordan JL, Frew AJ. Systemic cytokine levels in community-acquired pneumonia and their association with disease severity. Eur Respir J 2002; 20:990-5.
64. Greene C, Lowe G, Taggart C, Gallagher P, McElvaney N, O'Neill S. Tumor necrosis factor-α-converting enzyme: its role in community-acquired pneumonia. J Infect Dis 2002; 186:1790-6.
65. Salkind AR, Cuddy PG, Foxworth JW. Fluoroquinolone treatment of community-acquired pneumonia: a meta-analysis. Ann Pharmacother 2002; 36:1938-43.
66. Niederman MS. Guidelines for the management of community-acquired pneumonia. Current recommendations and antibiotic selection issues. Med Clin North Am 2001; 85:1-15.
67. Lieberman D, Schlaeffer F, Boldur I, et al. Multiple pathogens in adult patients admitted with community-acquired pneumonia: a one year prospective study of 346 consecutive patients. Thorax 1996; 51:179-84.
68. Marston BJ, Plouffe JF, File TM, et al. Incidence of community-acquired pneumonia requiring hospitalization: results of a population-based active surveillance study in Ohio. Arch Intern Med 1997; 157:1709-18.
69. Lim WS, Macfarlane JT, Boswell TCJ, et al. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: implications for management guidelines. Thorax 2001; 56:296-301.
70. Kauppinen MT, Saikku P, Kujala P, al et. Clinical picture of community-acquired Chlamydia pneumoniae pneumonia requiring hospital treatment: a comparison between chlamydial and pneumococcal pneumonia. Thorax 1996; 51:185-9.
71. Kleemola M, Saikku P, Visakorpi R, Wang SP, Grayston JT. Epidemics of pneumonia caused by TWAR, a new Chlamydia organism, in military trainees in Finland. J Infect Dis 1988; 157:230-6.
72. Acute respiratory infections, and influenza vaccine for 1999/2000. Commun Dis Rep CDR Wkly 1999; 9:87, 90.
73. Tan MJ, Tan JS, File TM Jr. Legionnaires disease with bacteremic coinfection. Clin Infect Dis 2002; 35:533-9.
74. Mundy LM, Oldach D, Auwaerter PG, et al. Implications for macrolide treatment in community-acquired pneumonia. Chest 1998; 113:1201-6.
75. Arancibia F, Bauer TT, Ewig S, et al. Community-acquired pneumonia due to gram-negative bacteria and Pseudomonas aeruginosa: incidence, risk, and prognosis. Arch Intern Med 2002; 162:1849-58.
76. Hatchette TF, Gupta R, Marrie TJ. Pseudomonas aeruginosa community-acquired pneumonia in previously healthy adults: case report and review of the literature. Clin Infect Dis 2000; 31:1349-56.
77. Lynch JP III. Hospital-acquired pneumonia: risk factors, microbiology, and treatment. Chest 2001; 119:373S-84S.